Results 271 to 280 of about 48,696 (305)
The trouble with dabigatran [PDF]
BMJ, 2014 Doctors and patients must tread carefully through emerging risks Options for stroke prevention in high risk non-valvular atrial fibrillation have recently broadened with the addition of new oral anticoagulants as an alternative to warfarin, the traditional and effective treatment.
Blake Charlton, Rita F. Redberg
openaire +2 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
International Journal of Stroke, 2020
Background Idarucizumab is a monoclonal antibody fragment with high affinity for dabigatran reversing its anticoagulant effects within minutes. Thereby, patients with acute ischemic stroke who are on dabigatran treatment may become eligible for ...
P. Kermer +72 more
semanticscholar +1 more source
Background Idarucizumab is a monoclonal antibody fragment with high affinity for dabigatran reversing its anticoagulant effects within minutes. Thereby, patients with acute ischemic stroke who are on dabigatran treatment may become eligible for ...
P. Kermer +72 more
semanticscholar +1 more source
Drugs, 2008
Dabigatran etexilate is an orally administered prodrug of dabigatran, which is a potent, concentration-dependent inhibitor of thrombus formation and thrombin-induced platelet aggregation. Dabigatran etexilate pharmacokinetics were linear across a wide dosage range.
Greg L. Plosker, Mark Sanford
openaire +3 more sources
Dabigatran etexilate is an orally administered prodrug of dabigatran, which is a potent, concentration-dependent inhibitor of thrombus formation and thrombin-induced platelet aggregation. Dabigatran etexilate pharmacokinetics were linear across a wide dosage range.
Greg L. Plosker, Mark Sanford
openaire +3 more sources
Dabigatran, bleeding, and the regulators [PDF]
BMJ, 2014 Thomas J Moore and colleagues highlight the differences in how US and European regulators managed the safety problems of the new anticoagulant dabigatran and ask both to think again and mandate plasma monitoring of ...
Donald R. Mattison +2 more
openaire +2 more sources
Dabigatran/Dabigatran etexilate
Drugs of the Future, 2005Because of the crucial role of thrombin in the coagulation cascade and platelet activation, the enzyme is a primary target for the development of anticoagulant and antithrombotic drugs. The peptidomimetic dabigatran and its oral double prodrug dabigatran etexilate are univalent direct thrombin inhibitors.
J. Castaner, J. Bozzo, L. A. Sorbera
openaire +2 more sources
Annals of Internal Medicine, 2020
BACKGROUND It is unclear whether anticoagulant type is associated with the risk for osteoporotic fracture, a deleterious complication of anticoagulants among patients with atrial fibrillation (AF).
W. Lau +9 more
semanticscholar +1 more source
BACKGROUND It is unclear whether anticoagulant type is associated with the risk for osteoporotic fracture, a deleterious complication of anticoagulants among patients with atrial fibrillation (AF).
W. Lau +9 more
semanticscholar +1 more source
Gastrointestinal disorders and dabigatran
Scandinavian Journal of Gastroenterology, 2012Anticoagulants play an important role in the prevention and treatment of a variety of acute and chronic thromboembolic disorders such as primary prevention and treatment of venous thromboembolism or prevention of stroke and systemic embolism in atrial fibrillation just to name of few.
Arthur Hoffman, Peter R. Galle
openaire +3 more sources
Idarucizumab for dabigatran overdose
Clinical Toxicology, 2016An overdose of oral anticoagulants represents a challenging scenario for emergency physicians. Dabigatran, an oral direct thrombin inhibitor, is increasingly used in place of warfarin. The lack of an antidote is a concern in patients who overdose on dabigatran, even though the drug can be eliminated with hemodialysis.
Laurens Liesenborghs +7 more
openaire +3 more sources